RDX-002

DRUG2 trials

Sponsors

Response Pharmaceuticals

Conditions

Cholesterol, ElevatedDrug-induced Weight GainTriglyceridesWeight Gain Trajectory

Phase 1

Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine

CompletedNCT05857566

Response PharmaceuticalsDrug-induced Weight Gain

Start: 2023-05-16End: 2023-09-13Updated: 2023-11-18

Phase 2

Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists

CompletedNCT06640972

Response PharmaceuticalsCholesterol, Elevated, Triglycerides, Weight Gain Trajectory

Start: 2024-09-27End: 2025-05-13Updated: 2026-07-02